Dianthus Therapeutics (DNTH) Accumulated Expenses (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Accumulated Expenses of $19.5 million for Q4 2025, up 48.78% year-over-year from $13.1 million in Q4 2024, and up 21.73% quarter-over-quarter from $16.0 million in Q3 2025.
Dianthus Therapeutics (DNTH) Accumulated Expenses (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $19.5 million for Q4 2025.
- In Q4 2025, Accumulated Expenses rose 48.78% year-over-year to $19.5 million; the TTM figure through Dec 2025 stood at $19.5 million (up 48.78% YoY), while the FY2025 annual figure was $19.5 million, up 48.78% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $19.5 million, up from $16.0 million in the prior quarter.
- The five-year high for Accumulated Expenses was $19.5 million in Q4 2025, with the low at $1.6 million in Q1 2023.
- The 5-year median for Accumulated Expenses is $7.4 million (2021), against an average of $8.5 million.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses sank 75.55% in 2023, then jumped 273.13% in 2024.
- Dianthus Therapeutics' Accumulated Expenses stood at $7.8 million in 2021, then fell by 15.53% to $6.6 million in 2022, then decreased by 1.57% to $6.5 million in 2023, then surged by 101.01% to $13.1 million in 2024, then jumped by 48.78% to $19.5 million in 2025.
- Business Quant data shows DNTH's Accumulated Expenses at $19.5 million in Q4 2025, $16.0 million in Q3 2025, and $14.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19.45 Mn |
| Sep 30, 2025 | 15.98 Mn |
| Jun 30, 2025 | 14.00 Mn |
| Mar 31, 2025 | 7.98 Mn |
| Dec 31, 2024 | 13.07 Mn |
| Sep 30, 2024 | 7.73 Mn |
| Jun 30, 2024 | 5.86 Mn |
| Mar 31, 2024 | 5.85 Mn |
| Dec 31, 2023 | 6.50 Mn |
| Sep 30, 2023 | 11.20 Mn |
| Jun 30, 2023 | 3.22 Mn |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | 6.61 Mn |
| Sep 30, 2022 | 6.72 Mn |
| Jun 30, 2022 | 5.79 Mn |
| Mar 31, 2022 | 6.41 Mn |
| Dec 31, 2021 | 7.82 Mn |
| Sep 30, 2021 | 8.26 Mn |
| Jun 30, 2021 | 8.15 Mn |
| Mar 31, 2021 | 7.09 Mn |